Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39

Benzinga Newsdesk www.benzinga.com Neutral 69.0%

Neg 0% Neu 69% Pos 0%

Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Overweight rating and announces Price Target of $39.